Home › Mild Cognitive Impairment › NCT04262206

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

Who can join

Ages 75 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Community-dwelling adults
* Age ≥75 years
* English or Spanish as primary language
* Able to provide a trusted contact

Exclusion Criteria:

* Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)
* Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)
* Dementia (clinically evident or previously diagnosed)
* Dependence in any Katz Basic Activities of Daily Living \[ADL\] (with the exception of urinary or bowel continence)
* Severe hearing impairment (preventing phone follow up)
* Unable to talk (preventing phone follow up)
* Statin use in the past year or for longer than 5 years previously (participant reported)
* Ineligible to take atorvastatin 40 mg (clinician determined)
* Documented intolerance to statins
* Active Liver Disease

About the study

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

What is being tested

• Atorvastatin 40 Mg Oral Tablet (drug)
• Placebo oral tablet (drug)

Sponsor: Duke University · Participants: 20,000 · Started: Sep 1, 2020

Contact the study team

• Pamela Monds · Phone: 9196688695
• Beth Harris · Phone: 9196688700

Official record on ClinicalTrials.gov — NCT04262206

Locations in the U.S.

Conditions

• Mild Cognitive Impairment
• Dementia
• Cardiovascular Disease

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.